Literature DB >> 20082620

A new basophil activation test using CD63 and CCR3 in allergy to antibiotics.

B Eberlein1, I León Suárez, U Darsow, F Ruëff, H Behrendt, J Ring.   

Abstract

BACKGROUND: Flow cytometric basophil activation tests (BAT) have been developed as cellular tests for in vitro diagnosis of IgE-mediated reactions. Different markers and techniques have been used after stimulation with various allergens.
OBJECTIVE: It was the aim of the present study to compare an established BAT (Flow-CAST) with a newly developed basophil activation protocol using CD63 and CCR3 (Flow2 CAST) in patients with type-I allergy to antibiotics.
MATERIALS AND METHODS: Twenty-four patients with a history of type-I allergy to antibiotics were examined. A careful allergy history was taken, and skin tests and determination of specific IgE antibodies were performed. Two different BAT using CD63 expression but different protocols were carried out after stimulation with different concentrations of antibiotics. Fifteen healthy subjects without a history of antibiotic allergy were studied as controls.
RESULTS: The Flow2 CAST showed a higher sensitivity than the Flow-CAST (55% vs. 53%) with regard to patients' history. Specificity was 80% both for the Flow2 CAST and for the Flow-CAST with regard to controls with negative history and negative RAST.
CONCLUSION: These results show the value of two different BAT as cellular tests in the in vitro diagnosis of patients with antibiotic allergy with equal specificity and a slightly higher sensitivity for the Flow2 CAST.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20082620     DOI: 10.1111/j.1365-2222.2009.03426.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  20 in total

1.  [Cellular in-vitro assays. Applicability in daily routine].

Authors:  B Wedi; A Kapp
Journal:  Hautarzt       Date:  2010-11       Impact factor: 0.751

2.  Testing Basophil reactivity in monitoring allergen specific immunotherapy: comments on Chirumbolo's paper.

Authors:  Claude Lambert
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Immunotherapy in allergy and cellular tests: state of art.

Authors:  Salvatore Chirumbolo
Journal:  Hum Vaccin Immunother       Date:  2014-05-02       Impact factor: 3.452

Review 4.  Pros and Cons of Clinical Basophil Testing (BAT).

Authors:  Hans Jürgen Hoffmann; Edward F Knol; Martha Ferrer; Lina Mayorga; Vito Sabato; Alexandra F Santos; Bernadette Eberlein; Anna Nopp; Donald MacGlashan
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

Review 5.  BAT in the Diagnosis of Drug Allergy: a Novel Tool in Clinical Daily Practice?

Authors:  Lucila Campos; Violeta Régnier Galvão; Jorge Kalil; Mariana Castells; Pedro Giavina-Bianchi
Journal:  Curr Allergy Asthma Rep       Date:  2019-03-11       Impact factor: 4.806

Review 6.  Practical guidelines for the response to perioperative anaphylaxis.

Authors:  Tomonori Takazawa; Ken Yamaura; Tetsuya Hara; Tomoko Yorozu; Hiromasa Mitsuhata; Hiroshi Morimatsu
Journal:  J Anesth       Date:  2021-10-14       Impact factor: 2.078

Review 7.  Update on the performance and application of basophil activation tests.

Authors:  Emily C McGowan; Sarbjit Saini
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

Review 8.  Recent applications of basophil activation tests in the diagnosis of drug hypersensitivity.

Authors:  Woo-Jung Song; Yoon-Seok Chang
Journal:  Asia Pac Allergy       Date:  2013-10-31

9.  Threshold for basophil activation test positivity in neuromuscular blocking agents hypersensitivity reactions.

Authors:  Natalia Hagau; Nadia Gherman-Ionica; Manuela Sfichi; Cristina Petrisor
Journal:  Allergy Asthma Clin Immunol       Date:  2013-10-23       Impact factor: 3.406

Review 10.  Basophil Reactivity as Biomarker in Immediate Drug Hypersensitivity Reactions-Potential and Limitations.

Authors:  Markus Steiner; Andrea Harrer; Martin Himly
Journal:  Front Pharmacol       Date:  2016-06-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.